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Abstract 
 
Candida glabrata has emerged as the second most prevalent fungal pathogen 
and its ability to form biofilms has been considered one of the most important virulence 
factors, since biofilms present a high tolerance to antifungal agents used in fungal 
infection treatment. The mechanisms of biofilm tolerance to antifungal agents remain 
poorly understood. Thus, the aim of this study was to evaluate the effects of fluconazole 
(FLU) in the formation and control of C. glabrata biofilms, its relation with the 
expression of genes encoding for ABC transporters, CDR1, SNQ2, and PDR1 and how 
the ergosterol biosynthesis may be affected.  
 Additionally to the high amounts of proteins and carbohydrates detected in the 
extracellular matrices in the presence of FLU, this work showed that the overexpression 
of efflux pumps is a possible mechanism of biofilm tolerance to FLU and this 
phenomenon alters the structure of C. glabrata biofilms by creating cell clusters. 
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Resumo 
 
Candida glabrata emergiu como o segundo fungo patogénico mais prevalente e a sua 
capacidade para formar biofilmes tem sido considerado um dos fatores de virulência mais 
importante, uma vez que os biofilmes apresentam elevada tolerância a agentes antifúngicos 
usados no tratamento de infecções fúngicas. Os mecanismos de tolerância dos biofilmes 
continuam por explorar. Por isso, o objetivo deste estudo é avaliar os efeitos do fluconazol 
(FLU) na formação e controlo dos biofilmes de C. glabrata, a sua relação com a expressão de 
genes que encodam os transportadores ABC, CDR1, SNQ2 e PDR1 e como a biossíntese do 
ergosterol pode ser afetada.  
Adicionalmente, para as grandes quantidades de proteínas e hidratos de carbono 
detetados nas matrizes extracelulares, na presença de FLU, este trabalho demonstrou que a 
sobre-expressão de bombas de efluxo é um possível mecanismo de tolerância dos biofilmes 
contra o FLU e este fenómeno altera a estrutura dos biofilmes de C. glabrata pela criação de 
agregados de células. 
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I.1. Background 
 
Most cases of candidiasis have been attributed to Candida albicans, but recently, 
non-Candida albicans Candida (NCAC) species, as Candida glabrata, have been 
identified as common pathogens. The incidence of systemic infections caused by C. 
glabrata increased dramatically throughout the 1990s and became the most common 
cause of candidiasis after C. albicans. Candida glabrata systemic infections are a 
subject of considerable concern due to the tendency of this species to rapidly develop 
resistance to azole antifungal agents, especially fluconazole, and polyenes like 
amphotericin B. Moreover, this species is also important due to the high mortality rates 
associated with C. glabrata fungemia. Adherence to host surfaces including medical 
devices, secretion of hydrolytic enzymes and specially biofilm formation are virulence 
factors that are associated with Candida pathogenicity.  
Biofilms formed by Candida isolates have been associated with higher 
morbidity and mortality rates compared with isolates unable to form biofilms, due to the 
significant resistance to antifungal therapy conferred by the complex biofilm structure 
and composition. Despite, the lack of knowledge about the exact mechanism of biofilm 
resistance to antifungals, it is believed that this is a complex multifactorial phenomenon. 
Actually, restricted penetration of drugs through the biofilm matrix, phenotypic changes 
resulting from a decreased growth rate or nutrient limitation, expression of resistance 
genes induced by contact with a surface and the presence of a small number of 
“persister” cells are hypothesized as mechanisms of biofilm resistance.  
At the present, little is known about C. glabrata biofilms resistance, so the aim 
of this project is to study the resistance mechanisms of C. glabrata biofilms to 
antifungal agents. It is expected that these studies will ultimately contribute towards the 
identification of targets for novel therapeutics against C. glabrata infections.  
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I.2. Objective 
 
The comprehension of resistance mechanisms of C. glabrata biofilms is the key 
to succeed on the Candida infections treatment, since the biofilms present much higher 
MICs for the common antifungal agents used, which in most cases, results on treatment 
failure. Thus, the main goal of this project is to study the resistance mechanisms of C. 
glabrata biofilms to fluconazole. To achieve this goal, the effects of FLU in the 
formation and control of C. glabrata biofilms, in the extracellular matrix composition 
was evaluated, as well as on ABC transporter genes expression (CDR1, SNQ2, PDR1) 
and on ERG genes (ERG1, ERG3, ERG6, ERG9, ERG11) that are involved in the 
ergosterol biosynthesis.  
Therefore, under the subject of this project it is expected to provide more 
knowledge for the development of new and more specific therapies for Candida 
infections, thus rising patients health and lowering the costs involved in the wrong 
application of these agents. 
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I.3. Structure of the thesis 
 
This dissertation is divided in six different chapters in order to present the work 
done during the time of investigation:  
 
I. Background and objectives  
This chapter will present the context and the objectives that gave wings to this thesis.  
 
II. Introduction 
This chapter will be focused in the theoretical basis associated to this work.  
 
III. Materials and methodology  
In this chapter the materials and the methods and techniques used in the experiments 
will be presented.  
 
IV. Analysis of the results  
In this chapter all results obtained during the whole experimental work will be included.  
 
V. Discussion of the results 
In this chapter the discussion of all the results obtained will be exposed. 
 
VI. Conclusions  
In this chapter the main conclusions obtained from the realized work will be presented 
and some works will be suggested to the future.  
 
VII. References  
The all bibliography used to the comprehension, execution and written of this 
dissertation will be listed in this chapter.  
 
The work presented in this thesis was developed in the Center of Biological 
Engineering, Department of Biological Engineering of the University of Minho.
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II.1. Candida Discovery 
 
“Thrush” was documented for the first time by Pepys in 1665. However, only in 
1846, a scientific approach to the study of thrush, carry out by Berg, showed the 
presence and relationship of the fungus with the disease. After these studies, the idea 
that the organism could cause several forms of the same disease became clear. In 1792 
and then in 1849, Frank and Wilkinson, respectively, observed that aphthae occurs not 
only in oral cavity but also in sexual organs and that a dimorphic fungus was the 
probable cause (Calderone 2002). 
Even so, the identity of the organism that causes the disease was only approved 
in 1954. Langenbeck was the first one that observed the fungus, in 1839, but the identity 
of the organism was incorrect. Then, in 1842, Gruby studied Langenbeck’s organism 
and concluded that it was a species of Sporotrichum. Five years late, Robin reclassified 
it as Oidium albicans (Calderone 2002)
 
It was only in 1923, that the generic name Candida was proposed to the 
organism responsible for thrush, when Berkhout proved that it was not a species of 
Monilia, but a fungus that grows in plant materials and clearly morphologically 
different from Candida, which was associated until that time. The whitish colonies on 
agar or the oral lesion of aphthae or thrush was probably the reason for the name 
Candida, which derived from the Latin phrase toga candida, which was used to 
describe a special white robe worn by candidates for the Roma Senate (Calderone 
2002).  
In the past 50 years, the number of new species of Candida described increased 
to approximately 150 (Calderone 2002).  
 
II.2. Candida Characteristics 
 
 Candida species are ubiquitous organisms and most of them are not human 
pathogens. The genus Candida is very heterogeneous and its principal characteristics 
will be described below. 
Chapter II - Introduction 
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II.2.1. Cell Biology 
The genus Candida is a genus consisting of yeasts that do not possess a known 
natural sexual cycle. Most Candida species exist as spherical to ovoid budding yeast 
cells or blastospores, typically 4 to 6 μm in diameter. Some Candida species are capable 
of producing chains of elongated  blastospores termed pseudohyphae both in vivo and 
under certain conditions in vitro. Table II.1 summarizes these properties, for some of 
the most relevant species (Calderone 2002). 
 
Table II. 1. Morphological characteristics of Candida albicans, Candida tropicalis, 
Candida parapsilosis and Candida glabrata species. Adapted from (Silva, Negri et al. 
2012). 
Species 
Germ 
tube 
Pseudohyphae 
Yeast size 
(μm) 
CHROM-agar 
colony colour 
C. albicans + +       4-6 x 6-10 Blue-green 
C. tropicalis - +       4-8 x 5-11 Dark blue 
C. glabrata - -            1-4 White, Pink-purple 
C. parapsilosis - +    2.5-4 x 2.5-9 White 
 
The cell wall of pathogens is critical to their interaction with host cells. For 
pathogenic fungi the cell wall represents the primary way in which the organism 
interacts with its host. 
Yeast and hyphal cell walls are similar qualitatively but different quantitatively 
in specific components, as chitin. Thus, the mycelial cell wall exhibited four- to fivefold 
higher level of chitin (Calderone 2002). 
The cell wall of Candida is approximately 80 to 90% carbohydrate and β-glucan 
(branched polymers of glucose), mannan (polymers of mannose) and chitin (polymers 
of β-1,4 N-acetyl-D) are the primary constituents. The most abundant component of 
Candida cell wall is β-glucan (β-1,3 and β-1,6 glucose polymer) that account fot 47 to 
60% of the weight of the cell wall, followed by mannoproteins that account for 
approximately 40% of the total cell wall polysaccharides, chitin that account for 0.5 to 
Chapter II - Introduction 
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3% and glycolipids that account for 1 to 7% by dry weight of the cell wall. 
Ultrastructural and biochemical observation revealed a layer arrangement: an inner wall 
composed of structural polysaccharides and an outer layer containing primarily mannan, 
mannoproteins or nonglycosylated proteins (Chauhan, Li et al. 2002).  
The biomolecules of the cell wall that are not found in mammalian cells are 
potential targets for the identification of antifungal agents.  
II.2.2. Growth Forms of Candida  
 The genus Candida is composed of an extremely heterogeneous group of 
organisms that grow as yeast, but most members of the genus also produce a 
filamentous type of growth (pseudohyphae, pseudomycelium). However, C. albicans 
and C. dubliniensis form true hyphae in addition to pseudohyphae. Thus, both species 
are considered polymorphic (Calderone 2002). 
 Pseudohyphae are formed from yeast cells or hyphae by budding, but the new 
cell remains attached to the parent one and elongates, resulting in filaments with 
constrictions at the cell-cell junctions of the filaments (Calderone 2002). 
 True hyphae are formed from yeast cells or as branches of existing hyphae. 
Outgrowths of the yeast cells (germ tubes) grow by apical extension and cross walls 
(septa) are formed behind the growing tip of the hyphae. Budding occurs laterally just 
behind the septa, the latter of which are perpendicular to the main axis of the hyphae 
(Calderone 2002). 
 The pseudohyphae appear to be an intermediate growth form of yeast and hyphal 
morphologies (Calderone 2002). 
Germination can be induced in complex media, chemically defined media and 
serum. Temperatures greater than 35 
o
C, pH of 6.5 to 7.0 or slightly alkaline and 
inoculum of <10
6
 mL
-1
 favor germination, whereas glucose as a sole carbon source, 
lower temperatures and an acid pH favor yeast growth (Calderone 2002). 
II.2.3. Virulence 
 Candida is a sophisticated pathogen. Although there are about 150 species of 
Candida, approximately 65% of Candida species are unable to grow at a temperature of 
37 
o
C, a prerequisite for an organism to be a successful pathogen (Calderone and Gow 
2002). There are several known virulence factors contributing to Candida pathogenicity 
that include adherence to epithelial and endothelial cells, proteinase production, hyphae 
Chapter II - Introduction 
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and pseudohyphae formation, phenotypic switching, phospholipase production and 
antigenic modulation as a result of pseudohyphae formation (Fidel, Vazquez et al. 
1999). 
 Adhesion is one of the most important virulence factors of Candida species. 
Adhesins are cell-surface components of Candida that promote host recognition and 
colonization (Calderone and Gow 2002). 
Most of the medically important species within the genus Candida possess the 
ability to produce pseudomycelium and are otherwise morphologically very similar. The 
interconversion of yeast forms to filamentous growth, a process named by 
morphogenesis, is associated with invasiveness of the organism and also contributes for 
virulence (Calderone and Gow 2002). 
The secretion of digestive enzymes such as the SAPs, a family of secreted 
aspartyl proteinases, and phospholipase B (PLB), is also required for their virulence 
since these hydrolytic enzymes can degrade host tissues and thus contribute for their 
invasion (Calderone and Gow 2002). 
 As opportunistic pathogens, Candida species can invade every tissue of the 
human body, depending on the integrity of the host immune system. Its capacity to live 
both as a commensal and pathogen, to evade the immune system, to overcome drug 
therapy, to invade a variety of body location and to adjust so rapidly to changes in host 
physiology suggests that it has extraordinary phenotypic plasticity and can adapt rapidly 
to environmental changes. “High-frequency phenotypic switching” can generate a 
variety of general phenotypes, occurs spontaneously, moreover can be affected by 
environmental changes and can have a profound effect on pathogenic traits. Switching 
is regulated by a number of phase-specific genes in a combinatorial fashion and a high 
proportion of these genes directly or indirectly have impact on pathogenesis and 
virulence (Soll 2002). 
The development of biofilms, the most prevalent growth form of 
microorganisms, is usually observed after initial attachment of Candida to host or/and 
medical devices. Biofilms are described as surface-associated communities of 
microorganisms embedded within an extracellular matrix and are an important virulence 
factors for a number of Candida species, as they confer significant resistance to 
antifungal therapy by limiting the penetration of substances through the matrix and 
protecting cells from host immune responses. Furthermore, biofilms formed by C. 
albicans, C. parapsilosis, C. tropicalis and C. glabrata isolates have been associated 
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with higher morbidity and mortality rates compared with isolates unable to form 
biofilms (Silva, Negri et al. 2012).
  
 
II.3. Non-Candida albicans Candida species 
 
 Candidiasis remains an important clinical problem, primarily in the 
immunocompromised patient population. Candida albicans initially was the most 
important pathogen but now non-Candida albicans Candida (NCAC) species, as 
Candida tropicalis, Candida parapsilosis, Candida glabrata, Candida krusei and 
Candida dubliniesis, have gained clinical importance (Moran, Sullivan et al. 2002; 
Silva, Negri et al. 2011). 
The apparent increased emergence of NCAC species in human candidiasis may 
be related to improvements in diagnostic methods, such as the use of chromogenic 
media with the ability to differentiate Candida species, as well as the introduction of 
molecular techniques in the routine diagnosis of fungemia. Nevertheless, the high 
prevalence of NCAC species in infections could also be a reflection of their inherent 
higher level of resistance to certain antifungal drugs compared to C. albicans, as this 
would promote their persistence in mixed species infections treated with traditional 
antifungal agents (Silva, Negri et al. 2012). 
NCAC species are a very heterogeneous group of organisms that are 
fundamentally different from each other and from C. albicans at the biological level 
(Table I). The virulence of different NCAC species in human and in animal models of 
infection varies considerably, for example, the ability or the inability to form 
pseudohyphae, the family of adhesins, the kind of hydrolytic enzymes produced 
(Moran, Sullivan et al. 2002). 
In the NCAC species, C. glabrata is considered relatively nonpathogenic in 
animal models, which suggests that it has few virulence attributes. However, high 
mortality rate has been associated to this Candida (Fidel, Vazquez et al. 1999). Few 
studies had been conducted on virulence of C. glabrata, that’s why great importance is 
given to this Candida in this work.  
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II.4. Candida glabrata 
 
Historically, C. glabrata was considered a relatively nonpathogenic saprophyte 
of the normal flora of healthy individuals, rarely causing serious infection in humans 
(Fidel, Vazquez et al. 1999). However, the incidence of systemic infections caused by 
C. glabrata increased dramatically throughout the 1990s and depending on the site of 
infection C. glabrata is often the second or third most common cause of candidiasis 
after C. albicans and is also the NCAC species most commonly recovered from the oral 
cavities of HIV-infected individuals (Fidel, Vazquez et al. 1999; Moran, Sullivan et al. 
2002). 
 Candida glabrata systemic infections are a subject of considerable concern due 
to  the tendency of this species to rapidly develop resistance to azole antifungal agents 
and due to the high mortality rate associated with C. glabrata fungemia (Moran, 
Sullivan et al. 2002). 
II.4.1. Epidemiology 
Data from the 90s show that approximately 31 to 55% of the oral cavity of 
healthy individuals is colonized by Candida species and this colonization increases with 
severity of illness and duration of hospitalization. Initially, C. albicans accounted for 70 
to 80% of the isolates recovered from infected patients, C. glabrata and C. tropicalis 
each accounted for approximately 5 to 8% of isolates, while other NCAC species occur 
only rarely. However, a change in epidemiology was observed. Although C. albicans is 
the most common fungal species isolated from blood, C. glabrata started to appear 
associated with an equally high mortality rate. The incidence of C. glabrata is higher in 
adults than in children and lower in neonates and, despite had being considered a 
relatively nonpathogenic saprophyte of the normal flora of healthy individuals and 
certainly not readily associated with serious infection in humans, it is of special 
importance because of its innately increased resistance to antifungal agents, specifically 
the azoles (Fidel, Vazquez et al. 1999; Hachem, Hanna et al. 2008; Silva, Negri et al. 
2012). 
More recently, in the United States, a study demonstrated that C. glabrata has 
increased as a cause of invasive candidiasis from 18% of all blood stream infection  
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isolates in the time period of 1992-2001 to 25% in 2001- 2007 with a concomitant 
increase in fluconazole resistance from 9% to 14%.
 
Another recent study demonstrated 
that resistance to both azoles and echinocandins was most prominent among isolates of 
C. glabrata with the highest resistance rates to echinocandins (16.7%), fluconazole 
(16.7%), posaconazole (5.0%) and voriconazole (11.0%) among isolates from the 20-
39-year age group (Pfaller 2012).
 
 
 The emergence of multidrug resistant (MDR) in C. glabrata is a real fear since 
that neither azoles nor amphotericin B are an optimal approach for therapy for C. 
glabrata infection (Pfaller 2012). For this reason, future surveillance efforts should 
focus on emergence of these potentially MDR strains of C. glabrata and the knowledge 
of the resistance mechanisms to antifungal agents should be a priority. 
II.4.2. Cell Biology 
Candida glabrata is a nondimorphic yeast that exists as small blastoconidia (1 to 
4 m) under some environmental conditions as a pathogen. In fact, C. glabrata is the 
only Candida species that does not form pseudohyphae at temperatures above 37 °C 
(Table II.1) (Fidel, Vazquez et al. 1999; Calderone 2002). 
On Sabouraud dextrose agar, C. glabrata forms glistening, smooth, cream-
colored colonies, which are relatively indistinguishable from those of other Candida 
species except for their relative size, which is quite small. On Chromagar, a differential 
medium that distinguishes Candida species by color as a result of biochemical 
reactions, C. glabrata colonies appear pink to purple, in contrast to C. albicans 
colonies, which appear green to blue-green (Table II.1) (Fidel, Vazquez et al. 1999; 
Calderone 2002). Among the critical distinguishing characteristics of C. glabrata are its 
haploid genome, in contrast to the diploid genome of C. albicans and several other 
NCAC species and its small-subunit rRNA (Fidel, Vazquez et al. 1999; Ernst and 
Bockmuhl 2002).
 
The biochemical reactions of C. glabrata are also quite distinct. Candida 
glabrata ferments and assimilates only glucose and trehalose, while C. albicans 
ferments and assimilates a high number of sugars (Fidel, Vazquez et al. 1999; 
Calderone 2002). 
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II.4.3. Virulence 
Candida glabrata is considered less pathogenic than C. albicans and other 
NCAC species, particularly in animal models of infection, although it is being 
associated with virulent infection in several immunocompromised individuals. C. 
glabrata adheres poorly to host surfaces and produces less proteinases than C. tropicalis 
and C. parapsilosis. Adhesins, cell surface proteins that are involved in specific 
adherence, encoded by EPA gene family are major group of adhesins in C. glabrata and 
it is known that EPA1p is a calcium-dependent lectin (Fidel, Vazquez et al. 1999; 
Moran, Sullivan et al. 2002; Silva, Negri et al. 2011; Silva, Negri et al. 2012).  
Haemolysins are considered key virulence factors since they enable pathogen 
grow in the host using haemin or haemoglobin as a source of iron. Luo (Silva, Negri et 
al. 2012) observed that C. glabrata is able to produce haemolysins in vitro, inducing 
partial or total erythrocyte lyses and showed that a haemolysinlike protein (HLP) gene 
was associated with the haemolytic activity of C. glabrata. But other authors only 
observed production of haemolysins by C. albicans (Silva, Negri et al. 2012).
 
 
It is known that C. glabrata is unable to produce filamentous forms (hyphae or 
pseudohyphae) in vivo an important virulence factor required for tissue invasion (Fidel, 
Vazquez et al. 1999; Moran, Sullivan et al. 2002).  
Switching was firstly reported in C. albicans, but it has been demonstrated in 
other Candida species such as C. glabrata, C. tropicalis and C. parapsilosis. Using an 
indicator agar 1 mM CuSO4, reversible switching in C. glabrata is demonstrated at high 
frequency between a white to light brown and dark brown colony phenotype. As in C. 
albicans, switching in C. glabrata is accompanied by the differential expression of 
genes: MT-II metallothionein gene and HLP gene that encodes a hemolysis-like protein. 
These genes are expressed in a graded fashion that correlates with the intensity of 
pigmentation. One of the genes is involved in copper detoxification while the other may 
be involved in red blood cell lysis which suggests that just as in the case of C. albicans, 
switching in C. glabrata is pleiotropic and again may represent a high order of virulence 
trait and play a role in causing symptomatic infections (Fidel, Vazquez et al. 1999; Soll 
2002). 
Biofilm formation is another virulence factor of C. glabrata, since biofilms limit 
the penetration of substances through the matrix and protect cells from host immune 
responses. The formation of mature biofilms and subsequent production of extracellular 
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matrix is strongly dependent on species, strain and environmental conditions (pH, 
medium composition, oxygen) and, in the case of C. glabrata, it was recently showed 
that a higher biofilm biomass is produced on silicone surfaces in the presence of urine, 
compared to C. parapsilosis and C. tropicalis. The opposite was found for biofilms 
formed in Sabouraud dextrose broth. Thus, biofilm formation by C. glabrata is lower 
compared with other NCAC species, when grown in rich culture media. Candida 
albicans biofilm matrix is mainly composed of carbohydrates, proteins, phosphorus and 
hexosamines. However,  Silva (Silva, Negri et al. 2012) reported that the extracellular 
matrix of C. glabrata biofilm is characterized by a high level of both proteins and 
carbohydrates, while the matrix of C. parapsilosis biofilm is mostly composed by 
carbohydrates and the matrix of C. tropicallis biofilm exhibits low levels of both 
proteins and carbohydrates (Silva, Negri et al. 2012). 
II.5. Mechanisms of Resistance to Antifungal Agents  
 
Both the frequency of invasive fungal infections (IFIs) and the resistance to 
antifungal therapy continue to increase, despite the introduction of new antifungal 
agents. In vitro susceptibility testing is often used to study resistance/sensibility to 
specific agents against microorganisms. Standardized methods for reliable in vitro 
antifungal susceptibility testing are now available from the European Committee on 
Antimicrobial Susceptibility Testing (EUCAST) in Europe. Epidemiologic surveys that 
examine local and regional data can be used to develop empiric treatment strategies and 
are essential in tracking resistance trends (Pfaller 2012). 
Various mechanisms can lead to the acquired resistance of Candida species to 
antifungal agents, like the induction of the efflux pumps encoded by the MDR or CDR 
genes and the acquisition of point mutations in the genes encoding for the targeted 
enzymes (Pfaller 2012). Moreover, it has been reported that biofilm formation confers 
significant resistance to the antifungal therapies (Baillie and Douglas 2000).  
Antifungal resistance is associated with elevated minimum inhibitory 
concentrations, poorer clinical outcomes, and breakthrough infections during antifungal 
treatment and prophylaxis (Pfaller 2012). 
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II.5.1. Antifungal Agents and Resistance 
The identification of antifungal drugs began in the late 1940s and continues 
today. 
 Antifungal treatments against Candida infections are hampered by several 
factors including the limited number of active agents, the emergence of refractory 
fungal species and the development of resistance. This situation has triggered the search 
for new antifungal agents with novel modes of action. Different cellular processes 
involved in the biosynthesis of components required for the growth of fungal cells have 
been targeted by antifungal agents (Sanglard and Bille 2002). Actually, the 
classification of these antifungal agents is based on their target of activity (Figure II.1).  
 
  
 
Ergosterol biosynthesis is specific to fungi and is necessary for their growth and 
this feature has been largely exploited for the design and isolation of antifungal agents 
such as polyenes and azoles (Sanglard and Bille 2002). Moreover, components of the 
fungi cell wall are also targets for some antifungal agents as for example echinocandins 
(Silva, Negri et al. 2012). 5-fluorocytosine (5-FC) is another drug currently used against 
Candida, which can be incorporated into RNA molecules and subsequently interferes 
with the synthesis of proteins (Sanglard and Bille 2002) (Figure II.1). 
Figure II. 1. Mechanisms of action of antifungal 
agents: target molecules. 
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Antifungal resistance can be defined as in vitro or clinical resistance. In vitro 
resistance can be subdivided into primary resistance and secondary resistance. Primary 
resistance (intrinsic or innate resistance) occurs when the organism is naturally resistant 
to the antifungal agent (e.g., C. krusei, which is known to be universally resistant to 
fluconazole). Secondary resistance (acquired resistance) is said to occur when the 
infecting organism or pathogen becomes resistant to the antifungal agent, in others 
words, its growth is inhibited by an antimicrobial agent concentration higher than the 
range seen for wild-type strains (Fidel, Vazquez et al. 1999). Clinical resistance is 
defined by the situation in which the infecting organism is inhibited by an antimicrobial 
concentration that is higher than could be safely achieved with normal dosing (Pfaller 
2012).  
Table II.2 presents the Minimum Inhibitory Concentrations (MICs) of 
amphotericin B, fluoconazole and voriconazole in C. albicans, C. glabrata, C. krusei, 
C. parapsilosis and C. tropicalis, data collected from EUCAST. 
 
Table II. 2. Minimum Inhibitory Concentration (MIC) of amphotericin B, 
fluoconazole and voriconazole (mg/L) in Candida spp. 
 C. albicans C. glabrata C. krusei C. parapsilosis C. tropicalis 
Amphotericin B 0.032 – 1 0.032 – 2 0.12 –  2 0.032 – 2 0.032 –  2 
Fluoconazole 0.12 – 128 2 – 128 8 – 128 0.12 – 8 0.12 – 128 
Voriconazole 0.004 – 0.25 0.016 – 4 0.016 –  2 0.008 – 0.12 0.008 – 16 
 
The action of antifungal agents (Figure 1) and the mechanisms of resistance 
against these antifungal agents in C. glabrata are described in the sections below. 
II.5.1.1. Polyenes 
 In 1950, Hazen and Brown (Sanglard and Bille 2002)  identified the first 
antifungal agent, a polyene called nystatin. Then, other polyene antifungal agents, as 
amphotericin B (AmB) (Figure II.2), were isolated by Vandeputte and Gold from 
Streptomyces nodosus. AmB can form soluble salts in both basic and acidic 
environments, is not orally nor intramuscularly absorbed, and is virtually insoluble in 
water. Systemic and renal problems are often encountered with AmB and to reduce its 
unwanted side effects, AmB has been formulated in liposomes, lipid complexes and 
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colloidal suspensions to allow the use of higher doses of AmB and reduce its toxic 
effects to mammalian cells.  
 
 
  
 
 
 
 
 
Polyenes bind to ergosterol (Figure II.3) in the bilayer membrane of susceptible 
fungi. Aqueous pores result from the interaction of polyene molecules linked to the 
membrane sterols, leading to altered permeability, leakage of vital cytoplasmic 
components and death of the organism. Polyenes can also bind to cholesterol, which 
accounts for much of their human toxicity. However, AmB has much higher affinity for 
ergosterol than for cholesterol (Sanglard and Bille 2002). 
 
 
 
 
 
 
 
Figure II. 2 Structure of amphotericin B (AmB). Adapted from (Doctor 
Fungus 2010 [http://www.doctorfungus.org/thedrugs/Ampho_Deoxycholate.htm] 
Figure II. 3. Mechanism of action of amphotericin B. Adapted from Doctor 
Fungus 2010 [http://www.doctorfungus.org/thedrugs/antif_pharm.htm]. 
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One of the mechanisms of resistance to polyenes is believed to result from the 
alteration of sterol content or composition in the cell membrane. It has been described 
that among Candida species, polyene resistance was usually due to defective ergosterol 
biosynthesis and most likely resulted from mutation in the ERG3 gene that produces 
altered 5,6-sterol desaturase activity. Mutation in ERG11 (gene encoding for lanosterol 
14α-demethylase, required for sterol biosynthesis) and in ERG6 (a gene that is required 
for normal membrane function, but is not essential for sterol biosynthesis) may generate 
polyene resistance. In C. glabrata isolates mutations in the ERG6 gene were observed 
(Silva, Negri et al. 2012). 
II.5.1.2. 5-fluorocytosine 
5-fluorocytosine (5-FC) belongs to the class of pyrimidine analogs that was 
developed in the 1950s as a potential antineoplastic agent. It is highly water soluble so it 
can be administrated by oral or intravenous routes (via) (Sanglard and Bille 2002).  
 
  
 
 
 
 
 
 
 
 
5-FC is taken up by fungal cells (Figure II.5) by a cytosine permease and is 
deaminated by a cytosine deaminase to 5-fluorouracil (5-FU). 5-FU is a potent 
antimetabolite that can be converted to a nucleoside triphosphate and when incorporated 
into RNA causes miscoding. In other hand, 5-FU can be converted to a deoxynucleoside 
which inhibits thymidylate synthase and thereby, DNA synthesis. 5-FC has low toxicity 
in mammalian cells, since cytosine deaminase is absent or poorly active in these cells. 
However, the conversion of 5-FC to 5-FU is possible by intestinal bacteria and therefore 
5-FC can show toxicity in oral formulation and 5-FU, despite being a potent anticancer 
agent, it is impermeable to fungal cells (Sanglard and Bille 2002). 
 
Figure II. 4. Structure of 5-fluorocytosine (5-FC). Adapted from Doctor 
Fungus 2010 [http://www.doctorfungus.org/thedrugs/Flucytosine.htm].
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Mechanisms of resistance to 5-FC are possible due to the multiple intracellular 
enzymatic steps required for its action. These include alterations in the target enzymes 
UMP pyrophosphorylase, cytosine permease and cytosine deaminase, or increased 
production of pyrimidines. Due to the multiple steps in its mode of action, including 
transport into the cell and deamination of the active compound, and due to its extremely 
narrow spectrum of action 5-FC is normally used only in combination with other agents, 
including amB and fluconazole (Silva, Negri et al. 2012). 
II.5.1.3. Azoles 
Since pharmaceutical industry attributed great importance to fungal diseases, 
more drugs have been developed, and the azoles are a good example. Miconazol was the 
first azole developed against fungus, followed by the discovery of the triazoles such as 
fluconazole (Figure II.6) and itraconazole that are less toxic than amphotericin B, 
although being fungistatic (Sanglard and Bille 2002). 
 
Figure II. 6. Structure of fluconazole (FLU). 
Adapted from (Doctor Fungus  2010 
[http://www.doctorfungus.org/thedrugs/Fluconazo
le.htm]) 
Figure II. 5. Mechanism of action of 5-fluorocytosine. Adapted from Doctor 
Fungus 2010 [http://www.doctorfungus.org/thedrugs/antif_pharm.htm].
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Azoles have a cytochrome P450 as a common cellular target in yeast or fungi. 
Cytochrome P450 is involved in the 14α-demethylation of lanosterol. The unhindered 
nitrogen of the imidazole or triazole ring of azole antifungal agents binds to the heme 
iron of the cytochrome P450 as a sixth ligand, thus inhibiting the enzymatic reaction 
(Figure II.7). As a result ergosterol content in the cell membrane is depleted, membrane 
structure and functions are altered, and fungal growth is inhibited
 
(Fidel, Vazquez et al. 
1999; Sanglard and Bille 2002; Pfaller 2012). 
 
 
 
 
 
 
 
 
 
 
 
There are four principal mechanisms of azole resistance that have been described 
in Candida species. The first mechanism is the induction of efflux pumps that lead to 
decreased drug concentration at the enzyme target within the fungal cell. In C. glabrata 
the efflux pumps are encoded by CgCDR1 and CgCDR2 genes and the up-regulation of 
these genes has been associated to azole resistance. The second mechanism common in 
Candida species is the acquisition of point mutation in ERG11. Thus, an altered enzyme 
is synthesized with reduced affinity for or incapacity to bind azoles. The third 
mechanism, which can be associated with the second one, is the overexpression of the 
altered target enzyme. However, the up-regulation of altered target enzymes does not 
appear to be a major cause of azole resistance in Candida. Finally, the last mechanism 
Figure II. 7. Mechanism of action of azoles. Adapted from Doctor 
Fungus  2010 [ http://www.doctorfungus.org/thedrugs/antif_pharm.htm]. 
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of azole resistance in Candida species involves the development of bypass pathways, 
which negate the membrane-disruptive effects of azole drugs that are associated with 
inhibited fungal growth. This has been linked with mutation of the ERG3 gene in certain 
resistant strains of Candida. A study (Pfaller 2012) in C. albicans demonstrated an 
additive nature of resistance mechanisms in Candida species for azoles: the control 
strain with basal expression of CDR and WT ERG11 genes in both alleles, as expected, 
has low MICs for both fluconazole and voriconazole by comparison with MICs for both 
azoles in the strain with overexpression of CDR and point mutations in both ERG11 
alleles that are much higher. In addition the MICs for fluconazole and voriconazole are 
approximately twice as high in the strain with basal CDR expression and point 
mutations in both ERG11 alleles as in the strain with basal CDR expression and a point 
mutation in only one of the ERG11 alleles. 
II.5.1.4. Echinocandins 
The first echinocandin isolated was anidulafungin in 1974. Later, in 1989, 
caspofugin (Figure II.8) was discovered and micafugin was the last to be synthesized in 
1990 (Cortés and Russi 2011).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure II. 8. Structure of caspofugin. Adapted 
from Doctor Funfus 2010 
[http://www.doctorfungus.org/Thedrugs/Caspofu
ngin.htm]. 
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The echinocandins – anidulafungin, caspofugin and micafungin – are 
lipopeptides that bind to 1,3-β-D-glucan synthase, enzyme responsible for the 
biosynthesis of 1,3--D-glucan (a component of the cell wall), causing the formation of 
a defective cell wall associated with cellular instability and lysis in yeasts and aberrant 
hyphal growth in molds (Figure II.9)  (Cortés and Russi 2011; Pfaller 2012). 
 
 
 
Reduced susceptibility or resistance of Candida to echinocandins has been 
linked with point mutations in two “hot-spot” regions (HS1 and HS2) of FKS1, the gene 
encoding for the major and presumed catalytic subunit of 1,3- -D-glucan synthase. 
This resistance mechanism has been demonstrated in C. albicans and NCAC species as 
C. glabrata, C. krusei, C. tropicalis, and C. dubliniensis. In C. glabrata, echinocandin 
resistance has also been associated with mutations in the FKS2 gene (Pfaller 2012
)
. 
Figure II. 9. Mechanism of action of echinocandins. Adapted from Doctor 
Fungus 2010 [http://www.doctorfungus.org/thedrugs/antif_pharm.htm]. 
Chapter II - Introduction 
26 
 
II.5.2. Biofilms 
The biofilm state is the preferred mode of growth of microorganisms in natural 
environments. In the past years, several reports have associated biofilms with over 65% 
of hospital-acquired infections. It has also been suggested that Candida strains with a 
high ability to form biofilms are generally more virulent than others (Williams, 
Kuriyama et al. 2011). 
The exact mechanism of biofilm resistance to antifungals remains unclear, but it 
is probably multifactorial. There are three possible mechanisms of biofilm resistance: 
restricted penetration of drugs through the biofilm matrix; phenotypic changes resulting 
from a decreased growth rate or nutrient limitation; expression of resistance genes 
induced by contact with a surface. It has also been suggested that a small number of 
“persister” cells are responsible for resistance (Douglas 2003). 
Regarding the restricted penetration, it has long been supposed that the matrix of 
extracellular polymeric material might exclude or limit the access of drugs to organisms 
in the deeper part of the biofilm.  To investigate if the matrix plays a role in the 
resistance of biofilms to antifungal agents, the susceptibility profiles of biofilms where 
compared between biofilms of C. albicans which have relatively little matrix and 
biofilms of C. albicans which produce much more matrix. No significant differences in 
susceptibility to any of the drugs tested were found, indicating that drug resistance is 
unrelated to the extent of matrix formation (Baillie and Douglas 2000). However, it had 
been shown, in another study (Baillie and Douglas 1999), that resuspended cells (which 
presumably had lost most of their matrix) were some 20% less resistant to amphotericin 
B than intact biofilms, suggesting that the matrix might play a minor role in drug 
resistance. 
Biofilm cells are known to grow slowly because of the limited availability of 
nutrients, particularly at the base of the biofilm. A slow growth rate is often 
accompanied by changes in cell surface composition, which could affect the 
susceptibility of the microorganisms to antifungal agents. To investigate if growth rate 
is an important modulator of drug activity in biofilms, the susceptibility of C. albicans 
biofilms to ampB was compared with that of planktonic cells, the both cases with 
several growth rates. It has been demonstrated that biofilms were resistant to the drug at 
all growth rates tested whereas planktonic cells were resistant only at low growth rates 
(Baillie and Douglas 1998). Another study (Baillie and Douglas 1998) demonstrated 
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that not only the low growth rates, but also other conditions of growth, like glucose and 
irion availability, can interfere with drug susceptibility. Glucose-limited and iron-
limited biofilms, grown at the same low rate, were equally resistant to amphotericin B. 
Iron-limited biofilms probably resemble the most to biofilms growing in vivo, as to the 
fact there is an abundance of iron in the human body, most of it is located intracellularly 
or tightly complexed to iron-binding glycoproteins, thus being relatively inaccessible to 
microorganisms.  
Microorganisms that form biofilms express an altered phenotype. To investigate 
the surface-induced expression of resistance genes, it had been identified genes that are 
activated or repressed in Candida biofilms compared with planktonic cells. Genes 
coding for multidrug efflux pumps are of particular interest, since the upregulation of 
these genes results in a multidrug-resistant phenotype. Candida albicans possesses two 
different types of efflux pump, ATP-binding cassette (ABC) transporters and major 
facilitators, which are encoded by CDR and MDR genes, respectively (Douglas 2003). 
A study (Ramage, Bachmann et al. 2002) has demonstrated that genes encoding both 
types of efflux pump are upregulated during biofilm formation and development. 
However, mutants carrying single or double deletion mutations in some of these genes 
were highly susceptible to fluconazole when growing planktonically but still retained 
the resistant phenotype during biofilm growth. These results strongly suggest that drug 
resistance in C. albicans biofilms is a complex process that cannot be explained by a 
single molecular mechanism. 
However, it has been demonstrated in vitro that caspofungin is effective against 
C. albicans and C. glabrata biofilms (Cateau, Berjeaud et al. 2001). Caspofungin 
inhibits the synthesis of 1,3--D-glucan, the major structural component of Candida cell 
walls, suggesting that glucan synthesis might be a particularly effective target for 
biofilms if the biofilm matrix also contains this polysaccharide (Kuhn, George et al. 
2002). 
 
II.6. Drug Efflux pumps 
 
There are two main drug efflux pumps classes, the ATP-binding cassette (ABC) 
transporters and the Major-Facilitator Superfamily (MFS) transporters that are involved 
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in the resistance to antifungal agents, particularly azoles (Richard D. Cannon, Erwin 
Lamping et al. 2009). 
II.6.1. Major-Facilitator Superfamily (MFS) 
The MFS transporters are proteins with transmembrane domains (TMD) subtract 
specific. These transporters uses an electronic gradient as driving force to efflux the 
drugs out of the cell (Figure II.10) (Richard D. Cannon, Erwin Lamping et al. 2009). 
 
  
 
 
 
 
 
 
 
 
 
 
 
However, there is a more evident relation with the resistance to azoles and the 
ABC transporters than with the MFS transporters. 
II.6.2. ATP-Binding Cassette (ABC) 
The ABC transporters are proteins localized in the cellular membrane and in the 
organelles membranes that contain TMD substrate-specific and nucleotide-binding 
domains (NBD). These transporters use the ATP hydrolyses to efflux the drug out of the 
cell (Figure II.11) (Richard D. Cannon, Erwin Lamping et al. 2009). 
Figure II. 10. Representation of a MFS 
transporter: efflux of drugs with influx of 
protons into the cell. Adapted from 
(Richard D. Cannon, Erwin Lamping et al. 
2009). 
Chapter II - Introduction 
29 
 
 
  
 
 
 
 
 
 
 
 
 
 
Regarding the  resistance to FLU acquired by C. glabrata cells, the 
transcriptional induction and upregulation of genes encoding  ABC transporters (CDR1, 
CDR2 and SNQ2) have been reported (Tscherner, Schwarzmüller et al. 2011; 
Samaranayake, Cheung et al. 2013). The Figure II.12 illustrates the CDR1 transporter: 
two identical halves, each with a hydrophilic N-terminal domain which contains 
units of the ATP-binding (Walker A and Walker B), followed by a C-terminal 
hydrophobic domain with six transmembrane segments (Richard D. Cannon, Erwin 
Lamping et al. 2009).   
 
 
 
 
 
 
 
  
 
  
Figure II. 11. Representation of an ABC 
transporter: efflux of drugs with ATP 
hydrolyses. Adapted from (Richard D. Cannon, 
Erwin Lamping et al. 2009). 
Figure II. 12. Representation of the hydrophilic N-terminal 
and the hydrophobic C-terminal domains. Adapted from 
(Richard D. Cannon, Erwin Lamping et al. 2009). 
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 On other hand, a mutation in the gene that encodes a regulator of multidrug transporter 
genes, PDR1, was associated with its upregulation. This fact contributes to upregulation of 
CDR1 and SNQ2 genes (Vermitsky and Edlind 2004). However, little is known about the 
mechanisms of C. glabrata biofilms resistance.  
 
II.7. Ergosterol 
 
  Ergosterol is a biomolecule that is one of the main components of fungus 
cellular membrane. Candida grown in presence of azoles has a reduction in the 
ergosterol content of membranes and also an accumulation of toxic ergosterol 
precursors, such as 14-α-methylergosta-8,24(28)-dien-3β,6α-diol (Richard D. Cannon, 
Erwin Lamping et al. 2009).  
 
Figure II. 13. Ergosterol biosynthesis pathway. Adapted from Wikipathways 2010 
[http://www.wikipathways.org/index.php/Pathway:WP343]. 
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  It was been reported an overexpression and mutation of several genes involved 
in the ergosterol biosynthesis pathway (Figure II.13) as ERG1, ERG3, ERG6, ERG9 and 
ERG11 (Antonia Geber, Hitchcock et al. 1995; Patrick Vandeputte, Guy Tronchin et al. 
2007; Richard D. Cannon, Erwin Lamping et al. 2009). 
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III.1. Organisms and growth conditions 
 
A total of four different Candida glabrata strains were used in this work. The 
reference strain C. glabrata 2001 from the American Type Culture Collection (ATCC), 
two oral isolate (AE2 and D1) from the biofilm group of the Centre of Biological 
Engineering, originally isolated from Clinic of Dentistry, Congregados, Portugal, two 
urinary (562123 and 513100) and two vaginal (534784 and 585626) tract isolates, both 
isolated from patients of the Hospital of S. Marcos, Braga, Portugal. The identity of all 
isolates was confirmed using CHROMagar Candida (CHROMagar, France) and by 
PCR-based sequencing using specific primers (ITS1 and ITS4) against the 5.8S subunit 
gene reference. Genomic DNA was extracted following previously described 
procedures (Williams, Wilson et al. 1995). The PCRs products were sequenced using 
the ABI-PRISM Big Dye terminator cycle sequencing kit (Perkin Elmer, Applied 
Biosystems, Warrington, UK). All Candida strains were subcultured on Sabouraud 
dextrose agar medium (SDA; Merck, Germany) at 37 
o
C for 48 h. 
 
III.2. Antifungal susceptibility tests 
 
Minimum inhibitory concentrations (MICs) for fluconazole (FLU; Sigma-
Aldrich, USA) were determined using the microdilution method, in accordance with the 
guidelines of the Clinical Laboratory Standards Institute (CLSI) (M27-A2). 
The FLU concentrations tested were of 5, 50, 312.5, 625 and 1250 mg ml
-1
 and were 
prepared in RPMI 1640 (Sigma-Aldrich, USA). Thus, a small colony of each strain 
cultured on SDA was suspended in 5 ml of saline solution (NaCl 0.85%) and the 
cellular density adjusted to turbidity equivalent to a 0.5 McFarland standard in saline 
buffer. The yeasts suspensions were diluted (1:100) in saline solution and afterward 
diluted (1:20) in RPMI 1640, according to the standard.   
Each Candida suspension (100 l) was added to the respective well of microtiter 
plates (Orange Scientific, Braine-l’Alleud, Belgium) containing 100 l of each specific 
concentration of FLU solutions. Controls without antifungal agents were also 
performed. The microtiter plates were incubated at 37 
o
C, and the MICs values 
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determined visually as the lowest concentration of FLU showing no yeast growth after 
48 h. Additionally, a volume (50 l) of each cell suspension treated with FLU was 
recovered to a new well and serial decimal dilutions (in phosphate-buffered saline; PBS 
0.1 M pH 7.5: NaCl 0.8%, KCl 0.02%, K2HPO4 0.02%, NaHPO412H2O 0.285%) were 
plated onto SDA. Agar plates were incubated for 24 h at 37 
o
C, and the total number of 
colony forming units (CFUs) was determined. The results were presented per Log10 
CFU per milliliter (Log10 CFU ml
-1
). The assays were performed in triplicate and on 
three separate occasions. 
 
III.3. Biofilm formation 
 
An inoculum of each yeast strain, obtained from SDA plates, was suspended in 
20 ml of Sabouraud dextrose broth (SDB; Merck, Germany) and incubated at 37 
o
C for 
18 h under agitation (120 rpm). Then, the cells were harvested by centrifugation at 3000 
g for 10 min at 4 
o
C and washed twice with 15 ml of PBS pH 7.5. Pellets were 
suspended in SDB and the cellular density adjusted to 2x10
7
 or 1x10
7
 cells ml
-1
 using a 
Neubauer counting chamber, to use according with each experiment. 
 
III.4. Fluconazole effect against pre-formed Candida glabrata biofilms 
 
In order to test biofilms resistance to FLU, C. glabrata biofilms were pre-formed 
during 24 h in SDB. For that, 200 l of each Candida suspension containing 1x107 cells 
ml
-1
 was added to the respective well of microtiter plates (Orange Scientific, Braine-
l’Alleud, Belgium) and incubated at 37 oC under agitation (120 rpm). After this time, 
the medium was totally aspired and the biofilm washed once with 200 l of PBS to 
remove non-adherent cells. At this time, the solutions of FLU (at 50, 625 and 1250 mg 
ml
-1
) were added to the specific wells and incubated at 37 
o
C for extra 24 h. Controls 
devoid of FLU were also incubated. The assays were repeated in triplicate on three 
different occasions. 
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III.5. Fluconazole effect on Candida glabrata biofilm formation 
 
In order to study the effect of FLU in the biofilm formation, FLU was added in 
the beginning of the formation process. For that 96-wells microtiter plates (Orange 
Scientific, Braine-l’Alleud, Belgium) were filled with increased concentrations of FLU 
(at 50, 625 and 1250 mg ml
-1
) diluted in SDB. At each well containing 100 l of each 
specific concentration of FLU was added 100 l of Candida suspension containing 
2x10
7
 cells ml
-1
. The microtiter plates were incubated at 37
o 
C under agitation (120 
rpm). Controls with Candida cells and without FLU were also performed. The assays 
were repeated in triplicate on three different occasions. 
 
III.6. Biofilm analysis 
 
III.6.1. Biofilm biomass determination 
Total biofilm biomass was quantified by crystal violet staining methodology 
(Silva, Henriques et al. 2009). For that, the medium was totally aspirated and the 
biofilms washed once with 200 l of PBS to remove non-adherent cells. The biofilms 
were fixed with 200 μl of methanol and removed after 15 min. The microtiter plates 
were allowed to dry at room temperature. Then, 200 μl of crystal violet (CV; 1%, v/v) 
were added to each well. After 5 min, the excess of CV was removed and for that, the 
biofilms were gently washed twice with water. Lastly, 200 μl of acetic acid (33%, v/v) 
were added to each well to release and dissolve the CV stain.  The absorbance of 
suspensions was measured at 570 nm and the results were presented as absorbance per 
unit area (Abs/cm
2
). The assays were performed fivefold and on three separate 
occasions. 
 
III.6.2. Biofilm cultivable cells determination 
The number of cultivable cells on biofilms was determined by the enumeration 
of colony forming units (CFUs). For both cases, the medium was aspired and the 
biofilms washed once with 200 l of PBS to remove non-adherent cells. Then, biofilms 
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were scraped from the wells and the suspensions were vigorously vortexed for 2 min to 
disaggregate cells from matrix. Serial decimal dilutions in PBS were plated on SDA and 
incubated for 24 h at 37 
o
C. The results were presented as total of CFUs per unit area 
(Log10 CFUs cm
-2
). The assays were performed in triplicate and on three separate 
occasions. 
 
III.6.3. Biofilm matrix composition 
In order to analyze the matrices composition, polysaccharides and proteins were 
quantified. For that, 250 l of C. glabrata suspensions (2x107 cells ml-1 in SDB) were 
placed into 24-wells microtiter plates (Orange Scientific, Braine-l’Alleud, Belgium) 
containing 250 l of FLU solutions diluted in SDB to a final concentration of 0, 50 and 
1250 mg ml
-1
. The biofilms were formed during 24 h at 37 
o
C under agitation (120 
rpm). Then, the medium was totally aspired and the biofilms washed once with PBS to 
remove non-adherent cells. Biofilms were scraped from the wells, concentrated in PBS 
and their dry weights were determined by weighting 1 ml of the suspensions. In order to 
separate the cells from the biofilm matrices, the suspensions were sonicated (Ultrasonic 
Processor, Cole-Parmer, Illinois, USA) for 30 s at 30 W and centrifuged at 8000 g for 5 
min at 4 
o
C to recover the supernatants containing the biofilm matrices (Silva, 
Henriques et al. 2009). Therefore, supernatants were filtered using 0.2 μm filters and 
used for polysaccharides and proteins quantification. For polysaccharides 
quantification, 0.5 ml of phenol (50 g l
-1
) and 2.5 ml of sulfuric acid (95-97%) were 
added to 0.5 ml of each supernatant, the mixtures were vortexed and the reaction was 
extended by 15 min at room temperature, according the Dubois method (Dubois, Gilles 
et al. 1956). The absorbance was read at 490 nm and the total of polysaccharides 
quantification was determined by extrapolation with a standard curve, using glucose as 
the standard. For protein quantification, BCA Kit (Bicinchoninic Acid, Sigma-Aldrich, 
St Louis, USA) was used according to the manufacturer’s instructions. The absorbance 
was read at 562 nm and the proteins quantified by extrapolation by standard curve, 
using bovine serum albumin (BSA) as the standard. The assays were repeated in 
triplicate on three different occasions. 
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III.6.4. Biofilm structure 
In order to examine the structure of biofilms, after formation in the presence or 
absence of FLU, they were observed by scanning electron microscopy. For that,  
biofilms formed as described above were dehydrated with ethanol (using 70% ethanol 
for 10 min, 95% ethanol for 10 min and 100% ethanol for 20 min) and air dried for 20 
min. Samples were kept in a desiccator until the base of the wells was removed for 
analysis. Prior to observation, the base of the wells were mounted onto aluminum stubs, 
sputter coated with gold and observed with an S-360 scanning electron microscope 
(Leo, Cambridge, USA). 
 
III.7. Gene expression analysis 
 
For the molecular approach only two Candida strains were selected, C. glabrata 
ATCC 2001 and C. glabrata 562123, the highest and the lowest resistant to FLU, 
respectively. 
 
III.7.1. Gene selection and primers design for quantitative real-time PCR 
Three genes (CDR1, SNQ2 and PDR1) were selected to study their expression in 
planktonic and biofilm cells in the absence and presence of FLU concerning ABC 
transporters and five genes (ERG1, ERG3, ERG6, ERG9 and ERG11) were selected to 
study their expression in planktonic and biofilm cells in the absence and presence of 
FLU concerning the ergosterol biosynthesis pathway. The gene sequences of interest 
were obtained from Candida Genome Database (CGD) and the primers for quantitative 
real-time PCR (qRT-PCR) were designed using Primer 3 (http://simgene.com/Primer3) 
web-based software and are listed in Table III. 1. In order to verify the specificity of 
each primer pair for its corresponding target gene, PCR products were first amplified 
from C. glabrata ATCC 2001 and C. glabrata 562123 genomic DNA.  
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Table III. 1. Primers used for quantitative RT-PCR analysis 
Sequence (5’→ 3’) Primer Target 
PCR product size 
(bp) 
TTGTTGGTGTTCCTGGTGAA Forward 
CDR1 142 
ATGGACCATGCTGTTTGTGA Reverse 
CGATGCACCAACCAAGTATG Forward 
SNQ2 130 
ACCACCGACAGTCATCAACA Reverse 
CGGTGAGTTGGCCCTTACAA Forward 
PDR1 171 
TTTAATGTCGGCGGTTTCGC Reverse 
CACCGGTTACACCGTCTTCT Forward 
ERG1 121 
CAGGACCTTGTCGTTACCGT Reverse 
CACCCAGTCGACGGTTACTT Forward 
ERG3 158 
TTGACAACTGGGTTGTTGGA Reverse 
CTTCGACAAAGTGTACGCGA Forward 
ERG6 108 
TAAACGGCGAAAGTACCACC Reverse 
ATTGTCCTTGCAGGTTTTGG Forward 
ERG9 119 
TCCTCGGCGTAGTCTCTGAT Reverse 
CTCCATACTTGCCATTCGGT Forward 
ERG11 123 
CTTCAGTTGGGTAACGCCAT Reverse 
GTTGACCGAGGCTCCAATGA Forward 
ACT1 164 
CACCGTCACCAGAGTCCAAA Reverse 
 
III.7.2. Biofilm and planktonic cells preparation 
Biofilms of the selected strains were grown in 96-wells microtiter plates (Orange 
Scientific, Braine-l’Alleud, Belgium) in three different conditions – 0 (control), 50 and 
1250 mg ml
-1
 of FLU – with a final concentration of 1x107 cells ml-1 during 24 h (as 
described above). After, biofilm formation the medium was aspired and the wells were 
washed with PBS pH 7.5 to remove non-adherent cells. Biofilms were then scraped 
from wells with 1 ml of PBS and sonicated (Ultrasonic Processor, Cole-Parmer, Illinois, 
USA) for 30 s at 30 W to separate the cells from the biofilm matrix. Cells were 
harvested by centrifugation at 8000 g for 5 min at 4 
o
C. Additionally, planktonic cells 
were grown in 25 ml Erlenmeyers in the presence of 0, 50 and 1250 mg ml
-1
 of FLU 
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with a final concentration of 1x10
7
 cells ml
-1
 also during 24 h.  Cells were harvested by 
centrifugation at 8000 g for 5 min at 4 
o
C and were washed once with 10 ml of 
phosphate buffered saline (PBS; pH 7.5). 
 
III.7.3. RNA extraction 
RNA extraction was performed using PureLink® RNA Mini Kit (Invitrogen, 
Carlsbad, USA). 
Prior to RNA extraction, a lysis buffer (PureLink® RNA Mini kit) was prepared 
adding 1% of ß-mercaptoethanol. Then, 500 l of lysis buffer and glass beads (0.5 mm 
diameter) were added to each pellet. These mixes were homogenized twice for 30 s 
using a Mini-Bead-Beater-8 (Stratech Scientific, Soham, UK). After cells disruption, 
the PureLink® RNA Mini Kit (Invitrogen, Carlsbad, USA) was used for total RNA 
extraction according to the manufacturer’s recommended protocol. To avoid potential 
DNA contamination samples were treated with RNase-Free DNase I (Invitrogen, 
Carlsbad, USA). The RNA extraction was performed at three different independents 
assays. 
 
III.7.4. Synthesis of cDNA 
To synthesize the complementary DNA (cDNA) the iScript cDNA Synthesis Kit 
(Bio-Rad, Berkeley, USA) was used according to the manufacturer’s instructions. For 
each sample 10 l of the extracted RNA was used at a final volume of 50 l of reaction. 
cDNA synthesis was performed firstly to 70 
o
C for 5 min and then 42 
o
C for 1h. The 
reaction was stopped by heating for 5 min at 95 
o
C. 
 
III.7.5. Quantitative Real-Time PCR (qRT-PCR) 
Real-time PCR (CF X96 Real-Time PCR System; Bio-Rad, Berkeley, USA) was 
used to determine the relative levels of CDR1, SNQ2 and PDR1 mRNA transcripts in 
the RNA samples, with ACT1 used as a reference candidal housekeeping gene. Each 
reaction mixture consisted of a working concentration of SsoFast EvaGreen Supermix 
(Bio-Rad, Berkeley, USA), 50 M of forward and reverse primers, and 4 l cDNA, in a 
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final reaction volume of 20 l. Negative controls (water), as well as, non-transcriptase 
reverse controls (NRT) were included in each run. The relative quantification of genes 
expression was performed by the Pfaffl method (Pfaffl 2001). Each reaction was 
performed in triplicate and mean values of relative expression were determined for each 
gene. 
 
III.8. Statistical Analysis 
 
Results were compared using a two-way ANOVA with the Bonferroni test, 
using GraphPad Prism 5 software. All tests were performed with a confidence level of 
95%.  
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IV.1. Fluconazole minimum inhibitory concentrations and its effect against 
Candida glabrata biofilms 
 
Minimum inhibitory concentrations (MICs) were determined using the 
microdilution method and by CFUs counts (Table IV.1). The results showed that all 
strains were resistant to FLU according to the MIC breakpoint of EUCAST which is 32 
mg l
-1 
(EUCAST), and that fungistatic activity was strain dependent (Table IV.1). The 
lowest values of MIC (40-50 mg l
-1
 and 50-312.5 mg l
-1
), were obtained for C. glabrata 
562123 and C. glabrata 513100, respectively, both isolated from urinary tract. On the 
other hand, C. glabrata ATCC 2001 exhibited the highest resistance, with MIC values 
equal or superior to 1250 mg l
-1
. It was also possible to observe that C. glabrata AE2, 
D1 and 585626 are extremely resistant to FLU, with MIC values ranging from 625 to 
1250 mg l
-1
. Candida glabrata 534784 presented an intermediate value of FLU 
resistance. 
 
Table IV. 1. Minimum Inhibitory Concentrations (MICs) of 
fluconazole against Candida glabrata strains 
Strains MIC (mg l
-1
) 
C. glabrata ATCC 2001 ≥ 1250 
C. glabrata AE2 625 - 1250 
C. glabrata D1 625 - 1250 
C. glabrata 534784 312.5 - 625  
C. glabrata 585626 625 - 1250 
C. glabrata 513100 50 – 312.5 
C. glabrata 562123 40-50 
 
To determine the susceptibility of biofilms to FLU 24 h biofilms were treated 
with different concentrations of this agent. Figures IV.1 A and B presented the mean 
and standard deviation (SD) values of the Log10 CFU cm
-2
 and its correspondent total 
biomass values (Abs570 cm
-2
),
 
for C. glabrata biofilms. As expected FLU concentration 
below the MIC values (50 mg l
-1
) did not cause any cell reduction and concentrations 
above the MIC values were also ineffective in controlling the biofilm population 
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(Figure IV.1 A). The same results were obtained when measuring biofilm total biomass, 
the exceptions were the strains ATCC 2001 and AE2 that showed a significant biomass 
reduction (P<0.01) in the presence of FLU of 1250 mg l
-1
. These data demonstrated that 
biofilms in general are much more resistant to FLU than their planktonic counterpart’s 
cells. 
 
 
In order to determine if FLU could prevent biofilm formation, biofilms were 
formed in the presence different concentrations of FLU (Figure IV.2 A and B). No 
significant reductions in the number of viable cells were observed for the lower 
concentration of FLU tested (Figure IV.2 A). Conversely, for higher values of FLU 
(range 625 mg l
-1
 to 1250 mg l
-1
), C. glabrata ATCC 2001 presented the highest 
reduction in presence of higher values of FLU applied (range 625 mg l
-1
 to 1250 mg l
-1
) 
(Figure IV.2 A). Nevertheless, only a 1.5-log10 of reduction was obtained in comparison 
to the control (P>0.05). Figure 2B presents the total biomass values of biofilms of 24 h 
formed in the presence of different concentrations of FLU. The data showed that higher 
concentrations of FLU led to lower values of total biomass for all C. glabrata strains 
Figure IV.1. Effect of fluconazole on C. glabrata pre-formed biofilms. Mean values 
of the logarithm of colony forming units normalized by unit of area (Log10 CFU cm
-2
) 
presented on pre-formed biofilms treated for additional 24 h with different FLU 
concentrations (A); Mean values of the absorbance at 570 nm normalized by unit of area 
(Abs570 cm
-2
) of C. glabrata biofilms treated for additional 24 h with different FLU 
concentrations (B). Error bars indicate the standard deviations. ** Indicates P<0.01 and 
statistically different from the control. 
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tested, with exception of C. glabrata 585626 and C. glabrata ATCC 2001. Curiously, 
biofilms of C. glabrata ATCC 2001 presented a significant increase in the total biomass 
values (P<0.01) at FLU concentration 50 mg l
-1
 comparatively to the controls (biofilms 
without FLU). Nevertheless, for the higher concentrations of FLU, 625 and 1250 mg l
-1
, 
it was observed a drastic and significant biomass reduction (P<0.001). Biofilms of AE2 
and 562123 strains presented a significant biomass reduction (P<0.01 and P<0.001, 
respectively) at FLU concentrations of 625 and 1250 mg l
-1
. The total biomass of C. 
glabrata 585626 biofilms was also significantly reduced (P<0.001) in presence of FLU 
concentration of 625 mg l
-1
.  
 
 
From the data presented it can be concluded that FLU does not impair biofilm 
cell viability but causes a reduction in biofilm total biomass assessed by CV method. 
So, it can be hypothesized that FLU might influence the production of biofilm matrix 
that accounts for the total biofilm biomass. To test that hypothesis, the matrices of the 
biofilms formed in the presence of FLU were extracted and analyzed. Furthermore the 
biofilm structures were observed by SEM.   
 
Figure IV.2. Effect of fluconazole on the control of C. glabrata biofilms. Mean values 
of the logarithm of colony forming units normalized by unit of area (Log10 CFU cm
-2
) 
(A); Mean values of the absorbance at 570 nm normalized by unit of area (Abs570 cm
-2
) 
(B), on 24 h C. glabrata biofilms formed in the presence of different FLU 
concentrations. Error bars indicate the standard deviations. **and *** indicates P<0.01 
and P<0.001, and consequently statistically different from its controls. 
Chapter IV – Analysis of the results 
 
48 
 
IV.2. Biofilm matrix composition and its structure 
 
For the study of biofilm composition and its structure only the most resistant (C. 
glabrata ATCC 2001) and the least resistant (C. glabrata 562123) strains were selected. 
The polysaccharides composition was determined by the phenol/sulfuric acid method 
(Figure IV.3A) and the protein content was determined with the BCA Kit (Figure 
IV.3B). In fact, for both strains, the quantities of polysaccharides increased significantly 
(P<0.001) in presence of the two FLU concentrations (Figure IV.3A). Moreover, the 
most FLU resistant strain had significantly (P<0.001) more polysaccharides than the 
lowest one. Regarding the presence of proteins in biofilm matrices, a significant 
increase was only observed for the highest FLU concentration tested, in both strains 
(p<0.001). Interestingly, it was in the lowest FLU resistant strain biofilm matrix that it 
was found more proteins (P<0.001), approximately twice, comparing with the most 
resistant one, in the presence of 1250 mg l
-1
 of FLU. 
 
 
 
 
 
 
 
 
 
 
 
SEM analysis was used to examine C. glabrata biofilms structure in the 
presence of FLU, and it is visible that C. glabrata biofilms are exclusively formed by 
Figure IV. 3. Effect of fluconazole on matrices composition of C. glabrata biofilms. Mean 
values of polysaccharides quantity (A); Mean values of proteins quantity (B), in milligrams 
per grams of biofilm (mg/gbiofilm) of dry biofilm grown for 24 h in the presence of different 
FLU concentrations. Error bars indicate the standard deviations. *, ** and *** indicates 
P<0.05, P<0.01 and P<0.001, and consequently statistically different from its controls. 
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yeasts (Figure IV.4), however with different biofilm structures. The biofilm formed by 
the reference strain presented a more continuous carpet (Figure IV.4I A), comparatively 
to C. glabrata 562123 (Figure IV.4II A). Interesting, it was observed that, when the 
biofilms were grown in the presence of FLU, the morphology of biofilms appears like 
clusters of cells (Figures IV.4I B, IV.4II B).It is also important to refer, that for the 
maximum FLU concentration, biofilm cells have a more concave aspect and seems to 
have a reduction on the extracellular matrix (Figure IV.4I C). As it happened with the 
reference strain biofilm, the formation of cell clusters is seen in the presence of FLU as 
well as an extracellular matrix reduction (Figures IV.4II B, C). However, the 
extracellular matrix of the two different biofilms in the presence of FLU seems to be 
different. This may be explained by the differences in polysaccharides and proteins 
contents, as showed above. 
 
IV.3. Gene expression of ABC transporters 
 
To study the influence of the biofilm phenotype in the expression of genes 
encoding for ABC transporters, the same two strains were used (the most and the least 
resistant).  
Figure IV.5 presents the mean n-fold expression levels of SNQ2, CDR1 and 
PDR1 in C. glabrata ATCC 2001 and in C. glabrata 562123 grown as planktonic cells 
and as biofilm, respectively, in the presence of two concentrations of FLU. In each 
graph the control bar is the absence of FLU. 
The overexpression of genes SNQ2, CDR1 and PDR1 was observed in 
planktonic cultures of the strains ATCC 2001 following the application of high 
concentrations of FLU (Figure IV.5A). This result might explain the high levels of FLU 
resistance that this strain exhibited (Figure IV.2). Conversely, the levels of expression 
these genes by C. glabrata 562123 planktonic cultures were not affected by FLU. This 
strain exhibited a 20-fold less resistance to FLU than ATCC 2001 (Table IV.1). 
Interestingly overexpression of genes SNQ2, CDR1 and PDR1 was observed in biofilms 
formed by both C. glabrata strains after treatment with FLU, which suggests that FLU 
might be inducing the expression of ABC transporter genes in the biofilm phenotype of 
both strains. 
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Figure IV. 4. Scanning electron microscopy images of C. glabrata. C. glabrata ATCC 2001 (I) and C. glabrata 562123 (II) biofilms formed in SDB 
for 24 h in the absence of FLU (A) or in the presence of 50 mg l
-1
 of FLU (B) or 1250 mg l
-1
 (C). The bar in the images corresponds to 20 μm for the 
magnification 1000x and 10 μm for the magnification of 3000x. 
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Figure IV. 5. Expression of ABC transporter genes. Mean values of n-fold 
expression levels of SNQ2 (I), CDR1 (II) and PDR1 (III) genes in C. glabrata ATCC 
2001 grown as planktonic cells (A) and as biofilm (B) and in C. glabrata 562123 grown 
as planktonic cells (C) and as biofilm (D) treated with 50 and 1250 mg l
-1
 of FLU. 
Comparisons are made with planktonic and biofilm grown in the absence of FLU. Error 
bars indicate the standard deviations. *, ** and *** correspond to P<0.05, P<0.01 and 
P<0.001, respectively. 
 
IV.4. Gene expression of ERG genes 
To study the influence of the biofilm phenotype in the expression of genes 
involved in the ergosterol biosynthesis, the same two strains were used (the most and 
the least resistant).  
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Figure IV. 6. Expression of ERG genes. Mean values of n-fold expression levels of 
ERG1, ERG3, ERG6, ERG9 and ERG11 genes in C. glabrata ATCC 2001 grown as 
planktonic cells (A) and as biofilm (C) and C. glabrata 562123 grown as planktonic 
cells (B) and as biofilm (D) treated with 50 and 1250 mg l
-1
 of FLU. Comparisons are 
made with planktonic and biofilm grown in the absence of FLU. Error bars indicate the 
standard deviations. *, ** and *** correspond to P<0.05, P<0.01 and P<0.001, 
respectively 
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Figure IV.6 presents the mean n-fold expression levels of ERG1, ERG3, ERG6, 
ERG9 and ERG11 in C. glabrata ATCC 2001 and in C. glabrata 562123 grown as 
planktonic cells and as biofilm, respectively, in the presence of two concentrations of 
FLU. In each graph the control bar is the absence of FLU. 
In the most resistant strain (ATCC 2001) no overexpression was observed in 
planktonic cultures when high concentrations of FLU were added (Figure IV.6A). 
Interestingly the overexpression of genes ERG3, ERG9 and ERG11 was observed in 
planktonic cultures of C. glabrata 562123 after treatment with FLU (Figure IV.6B). As 
the strain 562123 is 20-fold less resistant than the strain ATCC 2001 (Table IV.1), this 
suggests that the overexpression of ERG genes is not the key factor for FLU resistance 
in planktonic cells. 
Additionally, the expression levels of the ERG3, ERG6 and ERG11 genes in 
biofilms of C. glabrata ATCC 2001 were significantly affected by FLU concentrations 
(Figure IV.6C). ERG1, ERG9 and ERG11 genes in biofilms of C. glabrata 562123 were 
also overexpressed (Figure IV.6D). 
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V. 1. Discussion of the results 
  
The present study evaluated the effect of FLU on C. glabrata biofilm formation 
and control, through the quantification of cultivable cells, total biomass and matrix 
composition, and through the evaluation of the expression of genes involved in FLU 
resistance.  
To reach the goal of this study, antifungal susceptibility tests were performed 
according to CLSI methodology in order to select the most resistant and sensible strains. 
For that, the susceptibility of seven strains to FLU was determined and all exhibited 
resistance to FLU (Table IV.1), however the MIC values were strain dependent. The 
lowest resistant strain presented a MIC value ranging from 40 to 50 mg l
-1
. However, a 
concentration of 1250 mg l
-1
 was required to reduce all visible planktonic cells for three 
of the seven strains tested. These results are in agreement with other authors, who 
reported high variability on susceptibility of C. glabrata planktonic cells. In a recent 
study by De Luca (Luca, Guglielminetti et al. 2012) C. glabrata strains, presented lower 
MIC values of 0.25 to 32 mg l
-1
, while Grandesso (Grandesso, Sapino et al. 2012) 
reported that the MIC90 of C. glabrata was a little higher, 64 mg l
-1
. These differences, 
which highlight the strain variations, may be due to the strains used, with origin in 
different clinical isolates recovered from patients submitted to different dose therapies.  
It is well known that biofilms are much more resistant to antifungal agents than 
planktonic cells (Donlan and Costerton 2002), and biofilms are particularly resistant to 
FLU. Biofilms are the preferred mode of growth of microorganisms in natural 
environments (Williams, Kuriyama et al. 2011), and are described as surface-associated 
communities of microorganisms embedded within an extracellular matrix (Silva, Negri 
et al. 2012). Moreover, it has been reported that clinical isolates are able to form 
biofilms and have been implicated in high morbidity and mortality rates compared with 
clinical isolates unable to form biofilms (Silva, Negri et al. 2012). All strains used in 
this study were able to form biofilms and FLU had no effect on the biofilm cells 
viability. In fact FLU was not able to reduce cell viability when applied directly on 
biofilms (Figure IV.1A), and was not able to reduce biofilm formation (Figure IV.2A). 
These results were in agreement with those reported by other authors (Costerton, 
Lewandowski et al. 1995; Donlan and Costerton 2002), that showed that the biofilms 
need about 10 to 100 times more quantity of antifungal agent to be eradicated. Although 
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FLU did not impair biofilm cell viability it caused a reduction in biofilm total biomass 
specially when applied in high concentrations, this reduction is probability due to a loss 
in biofilm matrix (Figure IV.1B and Figure IV.2B). However, despite the reduction of 
total biomass, the quantities of polysaccharides and proteins undergo a significant 
increase in the presence of FLU (Figure IV.3). In this way, SEM was use to study the 
structure and the morphologies of biofilm cells (Figure IV.4). Notwithstanding the 
inherent destructive nature of the technique, by the possible loss of some cells and 
matrix during the dehydration process, SEM images demonstrated that the C. glabrata 
biofilms in the presence of FLU, for both strains, results on biofilms structure 
modifications. Namely, the formation of cell clusters in opposite to biofilms formed in 
the absence of FLU. This is in accordance with the high levels of polysaccharides and 
proteins in the extracellular matrix, which was proven to increase cell clustering in 
biofilms (Mack, Nedelmann et al. 1994; Koo, Xiao et al. 2010). The results point out to 
the fact that FLU might induce changes in C. glabrata biofilm structure and matrix 
composition. It can be speculated that FLU might be triggering the production and 
secretion of polysaccharides and proteins that make the biofilm structure more cohesive 
and less hydrated contributing to a lower uptake of crystal violet, and thus indicating a 
lower biomass. On the other hand, FLU might be stimulating the expression of genes 
involved in the efflux pumps, a well-known mechanism of FLU resistance (Vermitsky 
and Edlind 2004; Tscherner, Schwarzmüller et al. 2011; Samaranayake, Cheung et al. 
2013) that contributes to increasing the flow rate inside the biofilm leading to a biofilm 
structure in cluster form. To test this hypothesis the expression of ABC transporter 
genes (SNQ2 and CDR1) as well as the zinc finger transcription factor (PDR1) that 
regulates drug efflux pumps was measured in planktonic in biofilm cultures after being 
treated with FLU. 
Indeed, FLU induced the overexpression of the ABC transporter genes of the 
biofilm cells. It is important to emphasize that these genes were not overexpressed in 
the planktonic cultures of the less resistant strain. These transporter genes are associated 
with the mechanism of FLU resistance in C. glabrata.  Indeed,  studies of Burn (Brun, 
Bergès et al. 2004) and Vermitsky & Edlind (Vermitsky and Edlind 2004) had 
demonstrated an overexpression of both CDR1 and CDR2 (PDH1) in C. glabrata FLU 
resistant mutants, although the FLU resistance in C. glabrata planktonic cells was 
mainly due to CDR1 upregulation (Brun, Bergès et al. 2004). Sanguinetti (Sanguinetti, 
Posteraro et al. 2005) had also demonstrated the upregulation of CDR1 and CDR2 and, 
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a slight upregulation of SNQ2 in C. glabrata clinical isolates in the presence of FLU. 
Moreover, Sanglard (Sanglard, Ischer et al. 2001) showed that expression of SNQ2 was 
little affected by azole resistance in clinical mutant strains of C. glabrata. In our study, 
an upregulation of SNQ2 was detected but only in C. glabrata ATCC 2001 planktonic 
cells. Nevertheless, SNQ2 was express seven times less than CDR1, which is in 
accordance with Sanglard et al. 2001 evidences. Conversely to what has been described 
in literature, one of to the strains (C. glabrata 562123, the least resistant strain) was not 
able to increase CDR1 expression in the presence of high concentration of FLU in the 
planktonic state. Moreover, the expression of SNQ2 and PDR1 was downregulated, 
demonstrating incapacity of the planktonic clusters to respond to FLU by increasing the 
efflux pumps. Nevertheless, and as said above, these genes were overexpressed in the 
biofilm phenotype, rendering the biofilm much more resistant to FLU. This fact can be 
due to the diffusional limitation of FLU inside the biofilm matrix decreasing the amount 
of FLU that enters in contact with the biofilm cells. This way cells receive less 
concentration of FLU and have time to develop the mechanisms of resistance.  
Regarding the expression of ERG genes, the ERG11 gene plays an 
unquestionable role in FLU resistance of C. glabrata biofilms (Figure IV.6) (Antonia 
Geber, Hitchcock et al. 1995; Patrick Vandeputte, Guy Tronchin et al. 2007; Richard D. 
Cannon, Erwin Lamping et al. 2009) and, depending on the strain and in the FLU 
concentration, some of the other ERG genes may be overexpressed to increase 
resistance of the biofilm.  
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VI.1. Conclusions 
 
This study showed that the pattern of resistance to FLU is strain dependent. 
Moreover it was also demonstrated that biofilms of C. glabrata are much more resistant 
to FLU than planktonic cultures. One of the possible mechanisms of resistance is the 
overexpression of efflux pumps. The upregulation of the genes encoding for the efflux 
pumps influences the biofilm structure maybe by creating water channels through the 
biofilm structures creating cell clusters. This work showed for the first time that ABC 
transporter genes are implicated in C. glabrata biofilm tolerance to high FLU 
concentrations and influences biofilm structure and that the overexpression of some 
ERG genes is crucial to the resistance of these biofilms. 
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